CBAY News and Press, CymaBay Therapeutics Inc. From 01/24/23

CymaBay Therapeutics ( NASDAQ: CBAY ) announces the pricing the previously announced public offering of common stock and pre-funded warrants. The company to sell 10M shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. ...

CymaBay Therapeutics ( NASDAQ: CBAY ) +7.6% aftermarket on Monday announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by CymaB...

CymaBay Therapeutics ( NASDAQ: CBAY ) has entered into a collaboration and license pact with Kaken Pharmaceutical for the development and commercialization in Japan of CymaBay's investigational drug seladelpar for the treatment of primary biliary cholangitis. The advances str...

Advances strategy to partner seladelpar for PBC outside U.S. Brings in approximately $34.0 million upfront payment Japan represents an important market with no currently approved second line treatment NEWARK, Calif. and TOKYO, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Cy...

Summary 100% technical buy signals. 13 new highs and up 84.95% in the last month. Wall Street price targets from $8 to $14. The Chart of the Day belongs to the biopharma company CymaBay Therapeutics (CBAY). I found the stock by using Barchart's powerful screening funct...

CymaBay Therapeutics, Inc. (CBAY) Q3 2022 Earnings Conference Call November 14, 2022 16:30 ET Company Participants Paul Quinlan - General Counsel Sujal Shah - Chief Executive Officer Chuck McWherter - Chief Scientific Officer and President, R&D Dennis Kim...

CymaBay Therapeutics press release ( NASDAQ: CBAY ): Q3 GAAP EPS of -$0.28 beats by $0.02 . Held $153.4 million in cash, cash equivalents and investments as of September 30, 2022. For further details see: CymaBay Therapeutics GAAP EPS of -$0.28 beats by $0.02...

NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the ...

NEWARK, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced encouraging seladelpar data in pati...